Dexcom has purchased TypeZero — the company that developed the Control-IQ hybrid closed loop algorithm that Tandem is trialing in the t:slim X2 with expected release in 2019.
4 Likes
Not sure if that’s a good thing. What do you think?
2 Likes
What does that mean for Insulet? Aren’t they using Dexcom for their Horizon system? Does that mean that Dexcom users are better off going with the t:slim than with Omnipod in the long run?
How long before dexcom buys tandem?
I think you find great images that speak better than words!!
2 Likes
It might be a good thing. It helps keep the TypeZero technology from being proprietary to a single pump company, which gives it a better chance to stand up to Medtronic’s market power. Dexcom and Tandem and TypeZero have been cooperating on the next t:slim hybrid closed loop. Now that Dexcom has gotten the iCGM rating from the FDA, maybe the TypeZero algorithms become technology that can be used (for a fee) in any pump that is approved to work with iCGM devices. Probably Tandem would rather keep it proprietary to them, but I don’t know what the current contracts say.
Who knows? Maybe we’ll see a Pod that runs with G6 CGM and a TypeZero closed-loop algorithm. Perhaps that’s not the current plan, but it’s one possible future.
I think that’s unlikely. Dexcom has been asked this at quarterly conference calls, and they’ve said they aren’t interested in becoming a pump company. I think they would rather be the CGM that all the pump companies use for looping, not the CGM that one single pump company uses.
7 Likes
Exactly. That makes this great. It definitely helps to keep choice and competition going.
I would be shocked if this was not exactly the plan.
2 Likes